Literature DB >> 3952519

The antitumor effect of prednimustine in vitro and in vivo.

B Hartley-Asp.   

Abstract

Prednimustine is active against a wide variety of experimental tumors both in vivo and in vitro. In many of these tumor systems, prednimustine exhibits distinct advantages over a mixture of its constituents, chlorambucil and prednisolone. In vitro, a higher cell kill is obtained, and in vivo, at doses that are equally effective, prednimustine is less toxic. These differences could be connected with the different pharmacokinetic profiles found between prednimustine and chlorambucil plus prednisolone.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3952519

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  2 in total

1.  Continuous versus intermittent prednimustine treatment of non-Hodgkin's lymphoma.

Authors:  T Hatschek; L Baldetorp; J Carstensen; L Håkansson; T Möller; B Nilsson; B Termander
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

2.  Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro.

Authors:  E Musch; M Malek; J Peter-Katalinic; H Egge; H Rink; B Lathan; E Riedel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.